{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:35:55Z","timestamp":1791876955298,"version":"4.3.4"},"reference-count":88,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy has proven successful for B-cell lymphomas and leukemias. This success has inspired the development of CAR-T for T-cell malignancies. T-cell lymphomas and T-cell acute lymphoblastic leukemia (T-ALL) are highly heterogenous diseases but are united by poor prognosis in the relapsed\/refractory setting and the lack of any novel, targeted therapies. CAR-T therapy is a promising solution for these diseases but carries a number of challenges, principally that target antigens are typically shared between malignant and normal T cells. This can cause issues with fratricide and T-cell aplasia. In this review we discuss the current state of CAR-T treatment for T-ALL and T-cell lymphomas, highlighting recent novel clinical data for T-cell malignancies and discuss lessons that can be learned for future research in this area.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012263","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T20:56:37Z","timestamp":1734987397000},"page":"913-923","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-3723","authenticated-orcid":false,"given":"Nicola","family":"Maciocia","sequence":"first","affiliation":[{"name":"Department of Haematology, University College London Cancer Institute, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4015-5269","authenticated-orcid":false,"given":"Brandon","family":"Wade","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Cancer Institute, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9757-8073","authenticated-orcid":false,"given":"Paul","family":"Maciocia","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Cancer Institute, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"issue":"7","key":"2025032418220857800_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11864-020-00757-5","article-title":"Biology and treatment paradigms in T cell acute lymphoblastic leukemia in older adolescents and adults","volume":"21","author":"Patel","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"2025032418220857800_bib2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","article-title":"T-cell acute lymphoblastic leukemia","volume":"2016","author":"Raetz","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"8","key":"2025032418220857800_bib3","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00262-008-0632-0","article-title":"Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD\/Shi-scid, IL-2R\u03b3null mouse model","volume":"58","author":"Ito","year":"2008","journal-title":"Cancer Immunol Immunother CII"},{"issue":"12","key":"2025032418220857800_bib4","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"issue":"16_suppl","key":"2025032418220857800_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.10001","article-title":"Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed\/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study","volume":"40","author":"Hogan","year":"2022","journal-title":"J Clin Oncol"},{"issue":"18","key":"2025032418220857800_bib6","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab vedotin with chemotherapy in pediatric high-risk hodgkin\u2019s lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"2025032418220857800_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.2023023419","article-title":"CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2025032418220857800_bib8","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2025032418220857800_bib9","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.ymthe.2018.04.006","article-title":"Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice","volume":"26","author":"Pennell","year":"2018","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"7","key":"2025032418220857800_bib10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJM199902183400703","article-title":"Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency","volume":"340","author":"Buckley","year":"1999","journal-title":"N Engl J Med"},{"issue":"10","key":"2025032418220857800_bib11","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"2025032418220857800_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/vaccines11010165","article-title":"CAR T-cell immunotherapy treating T-ALL: challenges and opportunities","volume":"11","author":"Ren","year":"2023","journal-title":"Vaccines"},{"key":"2025032418220857800_bib13","doi-asserted-by":"crossref","first-page":"100150","DOI":"10.1016\/j.ejcped.2024.100150","article-title":"CAR T-cells for T-cell acute lymphoblastic leukemia","volume":"3","author":"Dourthe","year":"2024","journal-title":"EJC Paediatr Oncol"},{"key":"2025032418220857800_bib14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.05.018","article-title":"SOHO state of the art updates and next questions | CAR T cells in T cell acute lymphoblastic leukemia and lymphoblastic lymphoma","author":"Shmidt","year":"31  2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025032418220857800_bib15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.10.013","article-title":"Progress and pitfalls of chimeric antigen receptor T cell immunotherapy against T cell malignancies","author":"Angelos","year":"21  2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2025032418220857800_bib16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajh.2830450408","article-title":"Lineage determination of CD7+ CD5\u2212 CD2\u2212 and CD7+ CD5+ CD2\u2212 lymphoblasts: Studies on phenotype, genotype, and gene expression of myeloperoxidase, CD3\u03f5, and CD3\u03b4","volume":"45","author":"Yoneda","year":"1994","journal-title":"Am J Hematol"},{"issue":"11","key":"2025032418220857800_bib17","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1073\/pnas.76.11.5829","article-title":"Human lymphocyte antigens: production of a monoclonal antibody that defines functional thymus-derived lymphocyte subsets","volume":"76","author":"Haynes","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2025032418220857800_bib18","first-page":"5749","article-title":"Immunologic characterization of CD7-deficient mice","volume":"160","author":"Lee","year":"1998","journal-title":"J Immunol Baltim Md 1950"},{"issue":"5","key":"2025032418220857800_bib19","first-page":"2081","article-title":"CD7- T cells represent a subset of normal human blood lymphocytes","volume":"150","author":"Reinhold","year":"1993","journal-title":"J Immunol Baltim Md 1950"},{"issue":"4","key":"2025032418220857800_bib20","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025032418220857800_bib21","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ajh.27094","article-title":"Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy","volume":"98","author":"Zhang","year":"2023","journal-title":"Am J Hematol"},{"key":"2025032418220857800_bib22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.09.006","article-title":"Autologous CD7 CAR T cells generated without T-cell pre-selection in pediatric patients with relapsed\/refractory T-ALL: a phase I trial","author":"Zhao","year":"7  2024","journal-title":"Mol Ther"},{"issue":"13","key":"2025032418220857800_bib23","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025032418220857800_bib24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","author":"Oh","year":"3  2024","journal-title":"Nat Med"},{"issue":"30","key":"2025032418220857800_bib25","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"2025032418220857800_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"16","author":"Tan","year":"2023","journal-title":"J\u00a0Hematol OncolJ Hematol Oncol"},{"key":"2025032418220857800_bib27","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-4676375\/v1","article-title":"Anti-CD7 allogeneic WU-CART-007 in patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma: a phase 1\/2 trial","author":"Ghobadi","year":"5  2024","journal-title":"Res Sq"},{"issue":"11","key":"2025032418220857800_bib28","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"issue":"11","key":"2025032418220857800_bib29","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/s41375-023-02018-4","article-title":"CD7 targeted \u201coff-the-shelf\u201d CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies","volume":"37","author":"Li","year":"2023","journal-title":"Leukemia"},{"issue":"16","key":"2025032418220857800_bib30","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Yongxian","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"2025032418220857800_bib31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"2025032418220857800_bib32","article-title":"Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed\/refractory T-ALL","volume":"41","author":"Hill","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025032418220857800_bib33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03282-2","article-title":"Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial","author":"Pan","year":"1  2024","journal-title":"Nat Med"},{"issue":"S2","key":"2025032418220857800_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hon.3163_44","article-title":"First in human study of auto4, a Trbc1-tragetting cart T cell therapy in relapsed\/refractory Trbc1-positive peripheral T-cell lymphoma","volume":"41","author":"Cwynarski","year":"2023","journal-title":"Hematol Oncol"},{"key":"2025032418220857800_bib35","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0959-8049(22)00591-3","article-title":"The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9\u2013engineered CAR T cells in patients with relapsed\/refractory (R\/R) T-cell malignancies","volume":"173","author":"Zain","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"2025032418220857800_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0968-0004(94)90165-1","article-title":"The SRCR superfamily: a family reminiscent of the Ig superfamily","volume":"19","author":"Resnick","year":"1994","journal-title":"Trends Biochem Sci"},{"issue":"suppl 1","key":"2025032418220857800_bib37","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1182\/blood-2023-188043","article-title":"CD5 expression in mature T cell lymphoma","volume":"142","author":"Cao","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2025032418220857800_bib38","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4049\/jimmunol.136.2.505","article-title":"Leu-1+(CD5+) B cells. A major lymphoid subpopulation in human fetal spleen: phenotypic and functional studies","volume":"136","author":"Antin","year":"1986","journal-title":"Journal of immunology"},{"issue":"8","key":"2025032418220857800_bib39","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2025032418220857800_bib40","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.ymthe.2021.07.001","article-title":"The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains","volume":"29","author":"Dai","year":"2021","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"7","key":"2025032418220857800_bib41","doi-asserted-by":"crossref","first-page":"101628","DOI":"10.1016\/j.xcrm.2024.101628","article-title":"Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity","volume":"5","author":"Ma","year":"2024","journal-title":"Cell Rep Med"},{"issue":"13","key":"2025032418220857800_bib42","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood.2023022204","article-title":"Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas","volume":"143","author":"Hill","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025032418220857800_bib43","first-page":"1","article-title":"Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control","volume":"14","author":"Lin","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5994","key":"2025032418220857800_bib44","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/312541a0","article-title":"Complexity of human T-cell antigen receptor beta-chain constant- and variable-region genes","volume":"312","author":"Sims","year":"1984","journal-title":"Nature"},{"issue":"16","key":"2025032418220857800_bib45","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"2025032418220857800_bib46","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood.V75.1.174.174","article-title":"Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia","volume":"75","author":"Pui","year":"1990","journal-title":"Blood"},{"issue":"12","key":"2025032418220857800_bib47","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"issue":"1","key":"2025032418220857800_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-01002-0","article-title":"Dual T-cell constant \u03b2 chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry","volume":"14","author":"Horna","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025032418220857800_bib49","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41467-024-45854-3","article-title":"Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies","volume":"15","author":"Ferrari","year":"2024","journal-title":"Nat Commun"},{"key":"2025032418220857800_bib50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1155\/2012\/925135","article-title":"CD4+T cells: differentiation and functions","volume":"2012","author":"Luckheeram","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"2025032418220857800_bib51","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood.V87.3.893.bloodjournal873893","article-title":"Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody","volume":"87","author":"Knox","year":"1996","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032418220857800_bib52","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1182\/blood-2023-180111","article-title":"Phase I first-in-human study on the feasibility, safety, and antitumor activity of CD4-redirected chimeric antigen receptor (CAR) T-cell therapy in patients with CD4+ T-cell malignancies (TCM)","volume":"142","author":"Assi","year":"2023","journal-title":"Blood"},{"key":"2025032418220857800_bib53","doi-asserted-by":"crossref","first-page":"997482","DOI":"10.3389\/fimmu.2022.997482","article-title":"Treatment of aggressive T-cell lymphoma\/leukemia with anti-CD4 CAR T cells","volume":"13","author":"Feng","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"2025032418220857800_bib54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0092-8674(92)90180-K","article-title":"Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin\u2019s disease","volume":"68","author":"D\u00fcrkop","year":"1992","journal-title":"Cell"},{"issue":"9","key":"2025032418220857800_bib55","article-title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","volume":"7","author":"Weyden","year":"2017","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025032418220857800_bib56","doi-asserted-by":"crossref","first-page":"10488","DOI":"10.1038\/s41598-022-14523-0","article-title":"The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity","volume":"12","author":"Zhang","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"2025032418220857800_bib57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jncc.2021.07.001","article-title":"CAR-T and other adoptive cell therapies for B cell malignancies","volume":"1","author":"Lu","year":"2021","journal-title":"J Natl Cancer Cent"},{"issue":"9","key":"2025032418220857800_bib58","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"issue":"5","key":"2025032418220857800_bib59","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2352-3026(24)00064-4","article-title":"Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study","volume":"11","author":"Grover","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025032418220857800_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"S2","key":"2025032418220857800_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2438_148","article-title":"CD70 expression in cutaneous T cell lumphoma (CTCL) patients and mechanisms of action of ARGX-110 in skin: histopathological and clinical data","volume":"35","author":"Hultberg","year":"2017","journal-title":"Hematol Oncol"},{"issue":"14","key":"2025032418220857800_bib62","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas","volume":"132","author":"Scarf\u00f2","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2025032418220857800_bib63","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/sj.leu.2403822","article-title":"Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation","volume":"19","author":"Barrena","year":"2005","journal-title":"Leukemia"},{"issue":"7","key":"2025032418220857800_bib64","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-15-0067","article-title":"AGS67E, an anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B\/T-Cell Malignancies and AML: A New Role for CD37 in AML","volume":"14","author":"Pereira","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"2025032418220857800_bib65","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024104","article-title":"Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies","author":"Frigault","year":"23  2024","journal-title":"Blood"},{"issue":"1","key":"2025032418220857800_bib66","first-page":"1","article-title":"CCR9 in cancer: Oncogenic role and therapeutic targeting","volume":"9","author":"Tu","year":"2016","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"1","key":"2025032418220857800_bib67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.2021013648","article-title":"Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia","volume":"140","author":"Maciocia","year":"2022","journal-title":"Blood"},{"issue":"6241","key":"2025032418220857800_bib68","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/341447a0","article-title":"Recognition of cluster of differentiation 1 antigens by human CD4-CD8-cytolytic T lymphocytes","volume":"341","author":"Porcelli","year":"1989","journal-title":"Nature"},{"issue":"21","key":"2025032418220857800_bib69","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1182\/blood-2019-03-900910","article-title":"Anti-CD1a CAR T cells to selectively target T-ALL","volume":"133","author":"Maciocia","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2025032418220857800_bib70","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ni.3523","article-title":"CD1a on Langerhans cells controls inflammatory skin disease","volume":"17","author":"Kim","year":"2016","journal-title":"Nat Immunol"},{"issue":"21","key":"2025032418220857800_bib71","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","article-title":"Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia","volume":"133","author":"S\u00e1nchez-Mart\u00ednez","year":"2019","journal-title":"Blood"},{"issue":"19","key":"2025032418220857800_bib72","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1182\/bloodadvances.2020002502","article-title":"CD1a is rarely expressed in pediatric or adult relapsed\/refractory T-ALL: implications for immunotherapy","volume":"4","author":"Leong","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2025032418220857800_bib73","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","article-title":"Management of adults with T-cell lymphoblastic leukemia","volume":"129","author":"Marks","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2025032418220857800_bib74","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025032418220857800_bib75","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12916-023-03040-0","article-title":"CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK\/T cell lymphoma","volume":"21","author":"Li","year":"2023","journal-title":"BMC Med"},{"issue":"1","key":"2025032418220857800_bib76","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13046-022-02421-2","article-title":"Expanding anti-CD38 immunotherapy for lymphoid malignancies","volume":"41","author":"Wang","year":"2022","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"16","key":"2025032418220857800_bib77","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","article-title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","volume":"7","author":"Glisovic-Aplenc","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2025032418220857800_bib78","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/intimm\/10.8.1197","article-title":"Human B and T lymphocytes have similar amounts of CD21 mRNA, but differ in surface expression of the CD21 glycoprotein","volume":"10","author":"Braun","year":"1998","journal-title":"Int Immunol"},{"issue":"suppl 1","key":"2025032418220857800_bib79","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood-2021-145725","article-title":"Anti-CD21 chimeric antigen receptor (CAR)-T cells for T cell acute lymphoblastic leukaemia (T-ALL)","volume":"138","author":"Maciocia","year":"2021","journal-title":"Blood"},{"key":"2025032418220857800_bib80","doi-asserted-by":"crossref","first-page":"560971","DOI":"10.3389\/fimmu.2020.02109","article-title":"The chemokine receptor CXCR4 in cell proliferation and tissue regeneration","volume":"11","author":"Bianchi","year":"2020","journal-title":"Front Immunol"},{"issue":"14","key":"2025032418220857800_bib81","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/bloodadvances.2022008327","article-title":"Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma","volume":"7","author":"Watanabe","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2025032418220857800_bib82","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"2025032418220857800_bib83","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"issue":"20","key":"2025032418220857800_bib84","first-page":"2470","article-title":"Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma","volume":"141","author":"Roddie","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025032418220857800_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0705-x","article-title":"Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2025032418220857800_bib86","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","article-title":"T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape","volume":"7","author":"Dai","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"2025032418220857800_bib87","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1038\/s41375-021-01282-6","article-title":"Base-edited CAR T cells for combinational therapy against T cell malignancies","volume":"35","author":"Georgiadis","year":"2021","journal-title":"Leukemia"},{"key":"2025032418220857800_bib88","doi-asserted-by":"crossref","unstructured":"Tirado\n              N\n            , MansillaMJ, Martinez-MorenoA, . CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia. Published online 3 September 2024. https:\/\/doi.org\/10.1101\/2024.09.02.610843.","DOI":"10.1101\/2024.09.02.610843"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/913\/2356313\/blooda_adv-2023-012263-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/913\/2356313\/blooda_adv-2023-012263-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T19:59:36Z","timestamp":1742846376000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/4\/913\/534813\/CAR-T-cell-therapies-for-T-cell-malignancies-does"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012263","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]}}}